Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria T Acosta

Showing results (21-30 of 79) with videos related to

Pageof 8
Sort By:
Pediatric Neurology|September 13, 2011
Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I studyMaria T Acosta, Peter G Kardel, Karin S Walsh, et al.
Journal of Child Neurology|May 7, 2010
Cerebellar atrophy in human and murine succinic semialdehyde dehydrogenase deficiencyMaria T Acosta, Jeeva Munasinghe, Phillip L Pearl, et al.
Behavior Genetics|February 7, 2020
Neurofibromatosis Type 1 Implicates Ras Pathways in the Genetic Architecture of Neurodevelopmental DisordersJessica A Kaczorowski, Taylor F Smith, Amanda M Shrewsbury, et al.
Molecular Genetics & Genomic Medicine|September 22, 2016
ADGRL3 (LPHN3) variants are associated with a refined phenotype of ADHD in the MTA studyMaria T Acosta, James Swanson, Annamarie Stehli, et al.
Medrxiv : the Preprint Server for Health Sciences|September 19, 2025
Diffusion tensor imaging in Chediak Higashi DiseaseConnor J Lewis, Selby I Chipman, Cynthia J Tifft, et al.
Developmental Medicine and Child Neurology|November 21, 2012
Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1Karin S Walsh, Jorge I Vélez, Peter G Kardel, et al.
Journal of Child Neurology|September 2, 2021
Computerized Working Memory Training for Children With Neurofibromatosis Type 1 (NF1): A Pilot StudyKristina K Hardy, Carly Berger, Danielle Griffin, et al.
Biological Psychiatry|October 4, 2016
An Ultraconserved Brain-Specific Enhancer Within ADGRL3 (LPHN3) Underpins Attention-Deficit/Hyperactivity Disorder SusceptibilityAriel F Martinez, Yu Abe, Sungkook Hong, et al.
Medrxiv : the Preprint Server for Health Sciences|May 2, 2025
Brain Age Prediction in Type II GM1 GangliosidosisConnor J Lewis, Selby I Chipman, Precilla D'Souza, et al.
Journal of Child Neurology|June 13, 2026
Global Child Neurology Capacity Building Through the Child Neurology Society International Affairs Committee: From Needs Assessment to SMART Action GoalsSharoon Qaiser, Alcy Torres, Jorge Vidaurre, et al.
Pageof 8

Showing results (21-30 of 79) with videos related to

Sort By:
Pageof 8
Pediatric Neurology|September 13, 2011
Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I studyMaria T Acosta, Peter G Kardel, Karin S Walsh, et al.
Journal of Child Neurology|May 7, 2010
Cerebellar atrophy in human and murine succinic semialdehyde dehydrogenase deficiencyMaria T Acosta, Jeeva Munasinghe, Phillip L Pearl, et al.
Behavior Genetics|February 7, 2020
Neurofibromatosis Type 1 Implicates Ras Pathways in the Genetic Architecture of Neurodevelopmental DisordersJessica A Kaczorowski, Taylor F Smith, Amanda M Shrewsbury, et al.
Molecular Genetics & Genomic Medicine|September 22, 2016
ADGRL3 (LPHN3) variants are associated with a refined phenotype of ADHD in the MTA studyMaria T Acosta, James Swanson, Annamarie Stehli, et al.
Medrxiv : the Preprint Server for Health Sciences|September 19, 2025
Diffusion tensor imaging in Chediak Higashi DiseaseConnor J Lewis, Selby I Chipman, Cynthia J Tifft, et al.
Developmental Medicine and Child Neurology|November 21, 2012
Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1Karin S Walsh, Jorge I Vélez, Peter G Kardel, et al.
Journal of Child Neurology|September 2, 2021
Computerized Working Memory Training for Children With Neurofibromatosis Type 1 (NF1): A Pilot StudyKristina K Hardy, Carly Berger, Danielle Griffin, et al.
Biological Psychiatry|October 4, 2016
An Ultraconserved Brain-Specific Enhancer Within ADGRL3 (LPHN3) Underpins Attention-Deficit/Hyperactivity Disorder SusceptibilityAriel F Martinez, Yu Abe, Sungkook Hong, et al.
Medrxiv : the Preprint Server for Health Sciences|May 2, 2025
Brain Age Prediction in Type II GM1 GangliosidosisConnor J Lewis, Selby I Chipman, Precilla D'Souza, et al.
Journal of Child Neurology|June 13, 2026
Global Child Neurology Capacity Building Through the Child Neurology Society International Affairs Committee: From Needs Assessment to SMART Action GoalsSharoon Qaiser, Alcy Torres, Jorge Vidaurre, et al.
Pageof 8